Who is sponsoring NCT04124419?

NCT04124419 is sponsored by InMode MD Ltd..

What drugs are being tested in NCT04124419?

Interventions in NCT04124419: Treatment with Evolve System.

What condition does NCT04124419 study?

NCT04124419 studies Non-invasive Circumference Reduction.

Is NCT04124419 still recruiting?

NCT04124419 is currently completed. Last updated 27 February 2026.

Are results published for NCT04124419?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-02-27 · How we verify

NCT04124419

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Combined EMS and RF Treatments

Completed NA Results posted Last updated 27 February 2026

What this trial tests

NA trial testing Treatment with Evolve System in Non-invasive Circumference Reduction in 20 participants. Completed in 19 May 2021.

Timeline

19 July 2019

Primary endpoint
19 May 2021

19 May 2021

Quick facts

Lead sponsor	InMode MD Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	19 July 2019
Primary completion	19 May 2021
Estimated completion	19 May 2021
Sites	2 locations across United States

Drugs / interventions tested

Treatment with Evolve System

Conditions studied

Non-invasive Circumference Reduction — all drugs for Non-invasive Circumference Reduction →

Sponsor

InMode MD Ltd.

Who can join

Adults 18 to 65, any sex, with Non-invasive Circumference Reduction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Circumference Reduction Primary · Baseline to 6 months following last treatment session

Change in circumference measured in centimeters from baseline to 6 months following the last treatment session. Circumference was measured using a standard measuring tape. Negative values indicate a reduction in circumference.

Group	Value	95% CI
Treatment Arm	-0.86	-1.46 – 1.5

Change in Abdomen Area Appearance Assessed by Investigator Secondary · 6 month

\- Investigator assessment of the skin appearance comparing pre and post treatment using 0 - 4 -points Likert scale at follow up visits: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference Higher score = better improvement

Group	Value	95% CI
Treatment Arm	1.36	± 0.64

Subject Improvement Assessment Secondary · 6 Months

Improvement assessment will be performed independently by the subject himself using 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.

Group	Value	95% CI
Treatment Arm	1.9	± 1.23

Subject Satisfaction Assessment Secondary · 6 months

Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows: +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed. Higher scores indicate greater satisfaction.

Group	Value	95% CI
Treatment Arm	1.18	± 0.385

Sponsor's own description

The objective of this trial is to evaluate the safety and efficacy of the Evolve device utilizing the Ti10 and Tone applicators for abdominal non-invasive circumference reduction and skin tightening

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other InMode MD Ltd. trials

Trials by the same sponsor.

NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT06283498 — Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder · NA · enrolling by invitation
NCT06458556 — Transvaginal Radiofrequency Ablation for Overactive Bladder · NA · completed
NCT05830968 — Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne · NA · recruiting
NCT06283056 — RF Microneedling With Multi-Depth Targeting Per Insertion for The Treatment of Cellulite · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04124419 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InMode MD Ltd.
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04124419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing